Clinical Trials

1. Zoledronate with or without Thalidomide for Early Stage Multiple Myeloma (MC0289)
2. Study of IDEC-Y2B8 in the Treatment of Non-Hodgkin's Lymphoma
3. A Study of Daunorubicin and Gemtuzumab-Ozogamicin Therapies to Treat Adult Acute Myeloid Leukemia (E1900)
4. Imaging Cells in Monoclonal Antibody Therapy for Lymphoma
5. Drug Therapy Treatment of Relapsed and Refractory Non-Hodgkin's Lymphoma
6. Drug Therapy for the Treatment of Acute Myeloid Leukemia (AML)
7. A Study of Methotrexate to Treat LGL Leukemia (E5998)
8. A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia
9. C0701a/501, An Open-Label Extended-Use Study of Oral CEP-701 in Patients with Hematologic and Non-Hematologic Malignancies who have Completed a Clinical Study of CEP-701
10. MC0312, Phase I/II Study of Anti-CLTLA-A Monoclonal Antibody (MDX-010) in Follicular Non-Hodgkin's Lymphoma
11. AMD3100-CUP001, Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation
12. Zevalin Radionimmunotherapy with High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma (MC048A)
13. Genetic Epidemiology of B-Cell Lymphoproliferative Disorders
14. Daily Oral Polyphenon E in Asymptomatic Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia (MC0419)
15. A study to look at the dosing, safety, and tolerability of an Immunotherapy medication (CC-5013 or Revlimid) in children with relapsed/refractory solid tumors or myelodysplastic syndromes (ADVL0319)
16. RAD001 (Everolimus) for Relapsed or Refractory Lymphoma (MC048G)
17. VELCADE for the Treatment of Advanced Myeloproliferative Disorders (MC0486)
18. COX 2 Inhibitor (Celecoxib) for the Treatment of MGUS and Smoldering Myeloma (CN-25140)
19. Rituximab for Peripheral Neuropathy Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS)
20. Study Evaluating Types of Iron and Combining with Darbopoetin Alfa (Aranesp) for Cancer Patients Experiencing Anemia
21. Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
22. Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure or Patients over Age 60 in First Remission
23. Immunosuppressant, Alefacept (Amevive), in the Treatment of Cutaneous T-Cell Lymphoma and Peripheral T-Cell Non-Hodgkin Lymphoma (LS058C)
24. Treatment with Anti-CD30 Antibody, MDX-060 Combined with Chemotherapy, Gemcitabine (Gemzar); or MDX-060 in Combination with Dexamethasone (Decadron); or Gemcitabine Alone in Patients with Relapsed (Recurring) or Refractory (Resistant) Hodgkin's Disease
25. Monoclonal Antibody and Chemotherapy, R-CHOP, with Radioimmunotherapy, Zevalin, for Patients with Previously Untreated Stages 1 and 2 CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma
26. Revlimid (Lenalidomide), Cyclophosphamide (Cytoxan), and Dexamethasone (Decadron) for Patients with Newly Diagnosed Active Multiple Myeloma
27. Systemic Administration of (Edmonston Strain) of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide in Patients with Recurrent or Refractory Multiple Myeloma (MC038C)
28. Phase II Study of Cc-4047 (Actimid) or Cc-4047 (Actimid) Combined with Prednisone for Patients Diagnosed with Myelofibrosis with Myeloid Metaplasia (MMM)
29. Response-Adapted Therapy for Aggressive non-Hodgkins Lymphomas (NHL) based on early [18F] FDG-PET Scanning
30. A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkins Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
31. Phase 3 Trial Comparing Two Different Rituximab (Rituxan) Dosing Regimens for Patients with Indolent Non-Hodgkin Lymphoma
32. A Phase I and Pharmacological Clinical Trial of 17-Allylamino-17-demethoxygeldanamycin (17-AAG) and Cytarabine (Ara-C) in Refractory (Resistent) Leukemia and Myelodysplastic Syndrome (MDS)
33. A Phase II Study of CCI-779 (Temsirolimus, Torisel) in Combination with Rituximab (Rituxan) in Patients with Relapsed or Refractory (Resistent) Mantle Cell Lymphoma
34. Phase II Study with Azacitidine with or without (the Histone Deacetylase Inhibitor) MS-275 for the Treatment of Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CML) and Acute Myeloid Leukemia (AML)
35. Treatment Study for Patients Diagnosed with High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
36. A Phase 3 Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
37. Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
38. A Phase 3 Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease
39. A Phase 2 Study of SGN-40 (anti-huCD40 monoclonal antibody) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
40. A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of R935788 in Patients With Relapsed/Refractory (Resistant) B-Cell Lymphoma
41. A Phase I, Open label, Multicenter, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients with Advanced Malignancies
42. AMG 531 for Myelodysplastic Syndrome (MDS) Patients Receiving Lenalidomide (Revlimid)
43. Phase 2 Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation
44. MC0685, "A Phase II Study of Lenalidomide (Revlimid), Cyclophosphamide (Cytoxan) and Dexamethasone (Decadron) in Patients with Primary Systemic Amyloidosis"
45. A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma [Diffuse Large B-Cell Lymphoma (DLBCL)] Using Daily Enzastaurin (LY317615.HCl)
46. Comparing the Effects of 3 Different Dosing Regimens of Epoetin Alfa, a Medicine Used to Treat Anemia, and a Dosing Schedule of Darbepoetin Alfa, a Different Medicine Used to Treat Anemia, in Patients Diagnosed with Cancer
47. A Phase 3 Study of Dose-intensive Response-based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease
48. A Phase 3 Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine
49. A Phase 3 Clinical Trial of the Efficacy and Safety of Subsequent Treatment with the Zevalin (ibritumomab tiuxetan) Study Regimen Versus Observation in Patients with Diffuse Large B-Cell Lymphoma Who are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy
50. A Phase II Study of Sunitinib Malate (Sutent) for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
51. Study of the Monoclonal Antibody, Bevacizumab (Avastin) and CHOP (A-CHOP) (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Combination for Patients with Lymphoma Types of Peripheral T-Cell or Natural Killer Cell Neoplasms
52. A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy
53. CNTO 328, A Phase 2 Multicenter Study of CNTO 328 (Anti IL- 6 Monoclonal Antibody) in Patients with Relapsed or Refractory (resistant) Multiple Myeloma
54. A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma
55. A Phase 3 Study of Clofarabine and Cytarabine (ara-C) for Older Patients With Relapsed or Refractory (Resistant) Acute Myelogenous Leukemia (AML)
56. Phase 3 Vaccine Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with Acute Myelogenous Leukemia (AML) in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study
57. H23750, The Effect of Diflunisal (Dolobid) (IND 68092) On Familial Amyloidosis: A randomized, double blind, placebo controlled, international multi-center trial of Diflunisal on neurologic disease progression in 200 familial amyloidal patients
58. N0682, A Phase II Study of Denileukin Diftitox in Combination with Rituximab (Rituxan) in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma Patients
59. MC0784, Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (Rituxan) followed by Consolidation with Lenalidomide (Revlimid) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
60. MC0785, Antibody Therapy with Alemtuzumab (Campath), Rituximab (Rituxan), and GMCSF (Sargramostim) for Initial Treatment of High Risk Chronic Lymphocytic Leukemia (CLL)
61. Phase II Study of Rituximab (Rituxan) Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
62. Phase 2 Study to Evaluate the Safety and Efficacy of Monoclonal Antibody Lumiliximab in Combination with Fludarabine, Cyclophosphamide (Cytoxan), and Rituximab (Rituxan) Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
63. Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome (MDS)
64. A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
65. SG040-0005, A Randomized, Phase IIb Placebo-controlled Study of RICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
66. A Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory (Resistant) Multiple Myeloma
67. E1405, A Phase II Study of VcR-CVAD [rituximab (R), cyclophosphamide (C), doxorubicin (A), vincristine (V), bortezomib (Velcade) (Vc), and dexamethasone (decadron) (D)] with Rituximab (Rituxan) Maintenance for Untreated Mantle Cell Lymphoma
68. Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
69. A Phase II Study of the Combination of Cyclophosphamide (Cytoxan), Prednisone and Rituximab (Rituxan) (CPR) in Children, Adolescents and Young Adults with CD20 Positive Post-Transplant Lymphoproliferative Disease (PTLD) following Solid Organ Transplantation (SOT)
70. AAML0431, The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years
71. AHOD0521, A Phase II Study of Bortezomib (Velcade, PS-341, IND #58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease
72. Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
73. MC0788, "Phase II Trial of Low Dose Decitabine (Dacogen) in Patients with Primary Myelofibrosis and Post ET/PV Myelofibrosis"
74. Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia (ALL) That Has Relapsed in the Central Nervous System (CNS) or Testes
75. A Phase 2b Study of Molecular Responses to Imatinib (Gleevec) at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
76. AALL06N1, "A Study of Neurocognitive Function in Children Treated for Acute Lymphocytic Leukemia (ALL)"
77. Rituxan in Hemophilia A Patients Who Have Antibodies to FVIII.